Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25040572 | 0.73 | MEN1 (0.31) | MEN1KMT2AKDM4E | |
| SCHEMBL25038288 | 0.72 | KDM4E (0.33) | MEN1KMT2AKDM4E | |
| SCHEMBL29314726 | 0.66 | — | — | |
| SCHEMBL12254228 | 0.63 | MEN1 (0.39) | MEN1KMT2AKDM4E | |
| SCHEMBL27364280 | 0.62 | KMT2A (0.38) | MEN1KMT2AKDM4E | |
| SCHEMBL11576073 | 0.62 | MEN1 (0.38) | MEN1KMT2AKDM4E | |
| SCHEMBL11357164 | 0.61 | KMT2A (0.40) | MEN1KMT2AKDM4E | |
| SCHEMBL25091841 | 0.61 | KDM4E (0.37) | MEN1KMT2AKDM4E | |
| SCHEMBL4104481 | 0.61 | MEN1 (0.34) | MEN1KMT2AKDM4E | |
| SCHEMBL866289 | 0.60 | LMNA (0.53) | MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| WO-2023018215-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | 주식회사 빌릭스 | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | MEN1 3067/4885KMT2A 2003/4885KDM4E 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.